Searchable abstracts of presentations at key conferences in endocrinology

ea0090p303 | Calcium and Bone | ECE2023

SPECT/CT parathyroid scintigraphy in primary hyperparathyroidism: minimizing the risk of negative results by biochemical parameters assessment

Drynda Anna , Kucharczyk Karolina , Sokolowski Grzegorz , Trofimiuk-Muldner Malgorzata , Hubalewska-Dydejczyk Alicja

Primary hyperparathyroidism (PHP) diagnosis in clinical practice is based on biochemical blood tests. Since a single parathyroid adenoma causes about 85% of cases, the treatment of choice is parathyroidectomy, preceded by imaging studies. Ultrasound and [99mTc]sestamibi scanning can enable adenoma localization. However, the latter method is of higher sensitivity, especially if combined with anatomical imaging. In some cases, the radiotracer uptake in adenoma tissue ...

ea0099p452 | Calcium and Bone | ECE2024

Clustering of clinical and biochemical data for defining primary hyperparathyroidism ‘phenotypes’ and predicting parathyroid imaging results

Kucharczyk Karolina , Drynda Anna , Podlewski Jacek , Trofimiuk-Muldner Malgorzata , Hubalewska-Dydejczyk Alicja

Introduction: Primary hyperparathyroidism (PHPT) is a prevalent endocrinopathy typically identified through biochemical testing. PHPT is characterized by hypercalcemia accompanied by increased or inappropriately normal plasma parathyroid hormone (PTH) concentrations. Preoperative imaging is conducted when surgery is indicated to pinpoint parathyroid adenomas. MIBI scintigraphy is highly specific and sensitive in diagnosing PHPT, with a higher adenoma detection rate demonstrate...